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ABSTRACT
Background: Patients who have PTSD are particularly vulnerable to inefficient treatment
modalities and subsequent lifelong suffering. Multiple studies have exposed these inefficiencies
in conventional therapies and established a potentiality for MDMA use during psychotherapy
sessions in this patient population. Ketamine represents an anesthetic with a similar psychedelic
profile to MDMA that is used in current clinical settings.
Context: Mount Sinai Medical center is a 672-bed hospital in Miami Beach, Florida, where the
Miami Beach Anesthesiology Associates (MBAA) group provides anesthesia services. Many
procedures requiring anesthesia are carried out to a vast patient population, many of which are
patients with PTSD and associative symptoms of depression.
Objectives: The objective of the Evidence-Based Learning Module is to expand CRNA
knowledge of PTSD and the use of 3,4-Methylenedioxymethamphetamine (MDMA) assisted
psychotherapies in patients who have PTSD and other similar disorders.
Methods: A pre-implementation survey assessed the providers’ initial knowledge of PTSD,
including current treatment modalities and overall inefficiencies, and the pharmacology and
history of MDMA. A virtual educational intervention then followed this. When completed,
anesthesia providers were redirected to a post-intervention survey to establish the growth of
knowledge.
Results: Overall, there was an improvement in provider knowledge following the education
intervention. There was no change regarding the likelihood of researching MDMA further on the
CRNA’s own time.
Conclusions: Currently, there exist many insufficiencies in the treatment of patients with PSTD.
During the perioperative period, an area of heightened vulnerability for this population, a
universal standard of care or anesthetic plan specific to patients with PTSD is lacking. The
educational intervention provided was effective in improving anesthesia provider knowledge of
PTSD and MDMA.
Keywords: post-traumatic stress disorder, 3,4-methylenedioxymethamphetamine, ketamine

INTRODUCTION
The epidemiology of post-traumatic stress disorder (PTSD) includes many traumas and is
frequently associated with major depressive disorders (MDD). Despite several symptoms, varying
traumatic experiences, and a high PTSD or MDD frequency specific to this subgroup, effective
treatment modalities remain scarce. This proposes its own unique set of challenges in each facet
of the medical field, as patients with PTSD or MDD have reported higher rates of comorbid
disorders. Resultantly, this also includes a heightened need for medical and surgical services.1
The first-line treatment for PTSD is psychotherapy.2 According to the American
Psychological Association’s (APA’s) 2017 clinical practice guidelines, this involves TraumaFocused Cognitive Behavioral Therapy (TF-CBT) and Eye Movement Desensitization and
Reprocessing (EMDR).2 Even with patient compliance with these suggested modes of care, PTSD
persists as a lifetime disorder lacking total resolution in numerous cases.
The use of pharmacological therapy designated in PTSD management is limited. The
only medications currently approved by the Food and Drug Administration (FDA) for PTSD are
the selective serotonin reuptake inhibitors’ (SSRIs’) sertraline and paroxetine hydrochloride.3 Of
patients receiving SSRI therapy, a study by Thal et al4 concluded that only 20 to 30 percent had
reported any improvement. In a 2015 systematic review (SR) and meta-analysis by Hoskins et al5,
SSRIs were found to have a “minor effect” in reducing symptoms associated with PTSD in
patients. The insufficient evidence existing around PTSD and depression treatment efficacy
points to a demand for additional research.
Description of the Problem
3,4-Methylenedioxymethamphetamine (MDMA) is a substituted phenylethylamine first
synthesized in 1912 by the German pharmaceutical company Merck.3,6 There is a widespread
misconception of MDMA’s origin, with many reviews incorrectly citing it as evolving from the
development of an appetite suppressant. Following a systematic analysis of Merck’s archive
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documents, however, MDMA was ultimately recognized by the company as a precursor to a
hemostatic substance.6
In the 1970s, MDMA’s use in combination psychotherapy catalyzed communication
between patients and therapists. As MDMA was being utilized in this manner, published reports
suggested a specific value to its use with patients who experienced trauma and concurrent
depression. Before this method obtained momentum, MDMA also gained popularity as the main
constituent of the psychedelic drug Ecstasy. Subsequently, in 1985, MDMA was ruled as a
schedule one substance in the United States (US), making its use in therapy illegal and difficult to
research clinically.7
Ketamine shares a similar pharmacological history of trials and tribulations. Produced
initially with the intent of forming a shorter-acting analog of phencyclidine, Ketamine’s
psychedelic and dissociative properties also contributed to it gaining a reputation for recreational
use.8 Stimulatory effects of the drug predominate at lower doses, inducing hallucinatory
disassociations as well as an overall distortion of time and space that, much like MDMA, may be
appreciated in non-clinical settings.8
The properties that make Ketamine a proper anesthetic, such as cardiorespiratory stability
while maintaining sedation and analgesia, have simultaneously limited its usefulness as a
monotherapy agent. For example, even at subanesthetic doses, dissociative symptoms and
psychological effects may be too intrusive and not tolerated by patients. Following the
introduction of propofol in the 1970s, Ketamine’s use as an anesthetic grossly grew out of
popularity.8
Presently, the rising use of Ketamine in the clinical setting has facilitated an increasing
body of research. Ketamine represents an anesthetic with similar psychedelic propensities to
MDMA currently utilized to manage treatment-resistant depression (TRD). This subsequently
better establishes its effectiveness as a modality that can be expanded to patients with PTSD who
regularly suffer from associated depression. Despite working on differing neurological receptors,
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ketamine and MDMA yield comparable effects, and both may serve as catalysts to therapy.9
Suppose higher-level research existed on the specific use of MDMA in settings where Ketamine
has been nearly used exclusively. In that case, MDMA could become a valid alternative for
treatment.
Background
PTSD diagnoses are challenging to establish secondary to the heterogenicity of symptom
presentation. The need to explore past trauma often drives patients away from seeking medical
help, making the true prevalence of PTSD a challenging value to capture. According to the
National Comorbidity Survey Replication (NCS-R), the lifetime incidence of PTSD in adult aged
samples in the United States and Canada ranges from 6.1 to 9.2 percent.10 In the more recent
2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) study,
lifetime prevalence was concluded to be higher in women (8.6%) than men (4.1%).11 Among
individuals with lifetime PTSD, only 59.4 % sought care with an average of 4.5 years lapsing
from diagnosis to initial treatment.11 More up-to-date research is needed to capture the scope of
this issue in complete accuracy.
PTSD is a prevalent mental health disorder with longstanding effects and a high rate of
reoccurrence. PTSD contributes to reduced life quality and the development of comorbid
conditions such as depression, obesity, hypertension, additional mental health conditions, and
suicidality.7 Total resolution using traditional treatment modalities is an uncommon clinical
phenomenon.
The handling of patients presenting with PTSD and their concomitant depressive
symptoms also offers unique challenges to medical providers. Diagnosed and undiagnosed PTSD
in patients undergoing surgery, for example, demonstrate a higher rate of emergence delirium
(ED).12 ED is an experience characterized by altered mental perception, including confusion,
disorientation, illusion, agitation, and occasional violence following anesthesia’s cessation.12 This
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is a costly incidence associated with prolonged length of hospital stay and increased patient
morbidity and mortality.
PTSD and TRD are underappreciated clinical issues. Individuals specifically suffering
from previous traumas often do so silently, as exploring them through therapeutic interventions
may exacerbate symptoms. Additionally, medical providers rarely address the difficulties that
exist around treating PTSD and its associative conditions. Instead, they are often viewed as
individual experiences or isolated occurrences, contributing to the poor response rate to first-line
interventions.
MDMA’s overarching stigma of a drug primarily of recreational custom has limited its
useability in clinical investigation and psychotherapy.7 To establish the worth of MDMA in
practice, its current reputation must be overcome by collecting data from studies with high levels
of evidence. Reproducible examinations extending into phase 3 trials would rebuild MDMA’s
standing and significantly increase its possibility of use clinically.
The need for enhanced treatments for PTSD and its associative symptoms of depression
is supported by the disease’s overall prevalence in everyday medical practices and poor patient
outcomes with current strategies. The use of MDMA in a clinical setting, though proven both safe
and effective in various RCTs, requires additional evaluation before being taken seriously as a
potential treatment option. A review of the current evidence will support future studies’ indication
and strengthen MDMA’s usefulness in this manner, offering a hopeful future solution to patients.
Systematic Review Rationale
The rationale behind this SR is a foundation of inadequate pharmacotherapies that have
demonstrated reliable effectiveness in treating chronic PTSD or antidepressant-resistant (ADR).
Concerning an overall low response rate to first-line interventions, further investigation reveals an
area of medicine with a limited collection of research. When considering the commonality of
ADR and PTSD, this is an unjustifiable reality. Furthermore, the medications approved by the
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FDA, paroxetine, and sertraline, were outlined over two decades ago. The search or development
of novel medications has since remained stagnant.
Objectives of the Systematic Review
The purpose of this SR is to identify available evidence and evaluate each study’s
findings on the efficacy of MDMA-assisted psychotherapy in the treatment of chronic PTSD.
Following Johns Hopkins’ appraisal scale, the author then extrapolated level one and two
evidence, later establishing a direct comparison to Ketamine.13 The review also aims to assess a
potential new adjunct to traditional PTSD and TRD management. This SR includes the highestquality double-blinded RCTs, SRs, and meta-analyses that serve to answer the proposed PICO
(i.e., patient population, intervention or issue of interest, comparison intervention or group, and
outcome) question.13 The findings will ultimately be used to establish a basis of safety and
efficacy, supporting MDMA-assisted psychotherapy and expanding the knowledge of its use to
anesthesia providers. This SR answered the PICO question: “(P) In adult patients with chronic
PTSD and associative symptoms of depression, (I) how does the use of MDMA-assisted
psychotherapy (C) compare to ketamine-assisted psychotherapy (O) in the reduction of
symptoms?”
METHODOLOGY OF LITERATURE REVIEW
Search Strategy and Sources
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
checklist was used as a guide throughout the search.14 This review used the electronic databases
MEDLINE (ProQuest), Excerpta Medica Database (EMBASE), and Cumulative Index of Nursing
and Allied Health Literature (CINAHL) to find relevant articles. Keywords and concepts were
extracted from the PICO question and implemented into each database’s search table. The words
“post-traumatic stress disorder” OR “PTSD”; AND “ecstasy” OR “MDMA” OR “3,4Methylenedioxyamphetamine” OR “methylenedioxymethamphetamine” were implemented into
the search database and yielded 59 articles from CINAHL, 124 from MEDLINE, and 176 from
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EMBASE. The keywords “post-traumatic stress disorder” OR “PTSD”; AND “ketamine” was
then implemented into the same databases to find comparison articles. This yielded 43 articles
from CINAHL, 183 from MEDLINE, and 290 from EMBASE. Duplicate articles were removed,
and the remaining were initially screened according to publication dates, focusing on the last 5 to
10 years. The investigators organized the selected articles via EndNote into folders entitled
“CINAHL Ketamine”, “CINAHL MDMA”, “EMBASE Ketamine”, “EMBASE MDMA”,
“MEDLINE Ketamine”, and “MEDLINE MDMA”.
Study Selection and Screening of Evidence
Following consideration of the level of evidence, two investigators conducted a screening
based on the title and abstracts in relation to the preliminary PICO question. The remaining
studies were then critically appraised in a full-text analysis. Inclusion criteria comprised of:
articles published from 2010 to the present, adult patients with TRD or chronic PTSD, a PTSD or
TRD diagnosis as determined by a cutoff score on a validated measure, MDMA-assisted
psychotherapy, and ketamine-assisted psychotherapy. Exclusion criteria were defined as: articles
published before 2010, articles not written in English, patients under 18 years of age, patients
with acute PTSD, and PTSD or TRD diagnoses not determined by a cutoff score on a validated
measure. Although studies that included primary or secondary outcomes measured using the
Clinician-Administered PTSD Scale (CAPS) scoring were preferred, it did not warrant article
exclusion as this criterion would substantially limit the number of articles available for appraisal.
A total of 8 studies met the described inclusion criteria and were selected for this SR. A PRISMA
flow diagram in Figure 1 demonstrates a visual outline of this process.14
Table 1. Inclusion and Exclusion Criteria
Inclusion
Population:
• Adults (> 18 years old)
• Patients with TRD or chronic PTSD
Diagnosis:

Exclusion
Population:
• Children (<18 years old)
• Patients suffering from acute PTSD
• Patients suffering from acute depression
• Patients who were pregnant
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•

A PTSD or TRD diagnosis as
determined by a cutoff score on a
validated measure
Intervention:
• Studies on MDMA-assisted
psychotherapy in reducing the
experience of PTSD or TRD
• Ketamine-assisted psychotherapy in
reducing the experience of PTSD or
TRD
Primary or Secondary Outcomes:
• MDMA-assisted psychotherapy studies
that report a reduction in the experience
of PTSD or TRD
• MDMA-assisted psychotherapy studies
that report no change in the experience
of PTSD or TRD
• Ketamine-assisted psychotherapy
studies that report a decrease in the
experience of PTSD or TRD
• Ketamine-assisted psychotherapy
studies that report no change in the
experience of PTSD or TRD
Type of Study:
• English language
• Randomized Controlled Trials (RCTs)
• Case Studies
• Systematic Reviews
• Publication 2010- Present

•

Patient with concomitant comorbidities
in which MDMA/Ketamine therapy
would exacerbate (ex: CAD)
• Patients with substance
abuse/dependence
Diagnosis:
• PTSD or TRD diagnoses not determined
by a cutoff score on a validated measure
Intervention:
• Studies on MDMA-assisted
psychotherapy in reducing the
experience of anything other than PTSD
or TRD
Primary Outcomes:
• Anything other than PTSD or TRD
Type of Study:
• Non-English
• Questionnaire
• Theses
• Publication before 2010

Identification

Figure 1. PRISMA Flow Diagram

Records identified through
database searching
(n = 875)

Additional records identified
through other sources
(n = 0)

Included

Eligibility

Screening

Records after duplicates removed
(n = 621)

Records screened
(n = 254)

Full-text articles
assessed for
eligibility
(n = 18)

Studies included in
qualitative synthesis
(n = 8)

Records excluded
(n = 236)

Full-text articles
excluded, with reasons
(n = 10)
4 Wrong Study Design
1 Wrong Language
5 Wrong time frames

RESULTS OF LITERATURE REVIEW
Study Selection
In their totality, the selected peer-reviewed studies included a vast population of patients
possessing chronic, treatment-resistant PTSD or MDD. An exact number was not calculated, as
RCTs, SRs, and retrospective cohort studies were all included, with Varker et al., an SR, failing
to identify its patient total. With consideration of the studies that did determine their patient sums,
it is known that the studies in combination surpassed an entirety of 484 patients.
Study Characteristics
All reports were published between the years 2013 to 2020 in the English language. The
patient demographic characteristics did not vary significantly across all eight studies.
Interventional characteristics, however, did differ. This variation is secondary to a lack of
standardization around the clinical use of MDMA and the attempt to discover the most successful
way to administer it.
Definitions and Outcomes
To evaluate for PTSD symptom reduction, the primary measurement tool throughout the
literature was CAPS scoring. This method is a DSM-IV-based, structured interview designed to
quantify symptoms of PTSD.3 Criteria for PTSD are defined by a CAPS score of > 50, in addition
to having PTSD for at least six months.3,7,9,15,17
The mean age of all eight studies was between 36.4 to 52.1 years. Beyond their
psychological disorders, participants were regarded as healthy and lacked severe comorbid
cardiac, respiratory, and metabolic conditions that would put them at risk during Ketamine or
MDMA administration. By association and in conjunction with anesthesia considerations, this
could be defined by the American Society of Anesthesia (ASA) classification system as ASA
ones and twos. Additionally, studies required patients who admitted to previous substance abuse
or dependence to be abstemious for a defined period before enrollment in the study.
Risk of Bias
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The Cochrane Handbook Collaboration’s Risk of Bias tool was utilized to assess the risk
of bias in all studies.20 A low bias risk was maintained secondary to the randomized allocation of
patients among experimental groups, those receiving MDMA doses, and the control group, those
receiving placebo doses. Randomization was accomplished through web-based systems, as in
Mithoefer et al7 and Ot’alora et al15. The risk of bias in Murrough et al19 parallels this by
articulating its randomization scheme generated using permuted block randomization of size six.
Although double-blind randomization was carried out in Oehen et al3, performance bias was
difficult to ascertain within this study. Specifically, there is a failure to distinguish how individual
assignments between groups were concealed from investigators.
In Feder et al17, the randomized allocation of patients between experimental and control
groups maintained the double-blind. Bias risk remained low throughout the study because only
the research pharmacy was aware of the drug identity. Other individuals, such as the
anesthesiologists, patients, and data analysts, were blinded to randomization order.17
In the retrospective study by Hartberg et al.,16 there is a moderate risk of bias. Although
records were concealed and standardization of therapy design was followed, a risk of reporting
bias exists inherent to the fact that the clinical setting was a private, suburban psychiatric practice
with clinicians who had been previously utilizing Ketamine as augmentation therapy for over
three years.16 Comparatively, the SR by Li et al18 demonstrates a low risk of bias as each study
addressed randomization and maintenance of concealment, though specific modalities were not
discussed at length.
The risk of attrition bias cannot be overlooked, as many studies spanned over several
years. Specifically, Feder et al17, Ot’alora et al15, and Oehen et al3 had participants withdraw from
their trials. Feder and Oehen disclose why, credited to adverse effects from MDMA or Ketamine
infusions, one participant found a job, one failed to follow up, one was removed due to delayedonset sedation, and one was removed due to low baseline PTSD symptoms.15,17 Alternatively,
Oehen et al3 fail to acknowledge the rationale behind one of their participant’s discontinuations.
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DISCUSSION OF THE LITERATURE REVIEW
Summary of Evidence

Three RCTs were appraised that formatted their study into experimental cohorts
receiving active doses of MDMA and control cohorts receiving inactive, placebo doses.
Active dosages were defined as 100 or 125 milligrams (mg) by Ot’alora et al15, 75 mg to
125 mg by Mithoefer et al7, and 125 mg followed by 62.5 mg supplementation doses two
and a half hours later by Oehen et al.15 Inactive dosing was identified as 40 mg, 0 to
40mg, and 25 mg, followed two and a half hours later by 12.5 mg, respectively.3,7,15
All RCTs were consistent in reporting that therapeutic doses of MDMA in
conjunction with psychotherapy generated more significant decreases in CAPS scoring
compared to the control.3,7,15 Oehen et al, however, did not deem the overall reductions as
statistically significant (p = 0.066) at the defined initial endpoints of the study (baseline,
three weeks after the second and third MDMA infusion, and at the 2-month and 1-year
follow-up).3 Statically and clinically significant self-reported improvement was only
described according to the Posttraumatic Diagnostic Scale (PDS) (p = 0.014).3 The Oehen
et al study waivers from the previously discussed methodologies by proposing
supplemental dosing to all participants in both study groups. Specifically, the active, fulldose group received 125 mg of MDMA followed two and a half hours later by 62.5 mg,
whereas the active placebo group was dosed initially with 25 mg followed by 12.5 mg in
the same time frame.3
With participants randomly assigned between experimental and control groups.
Ot’alora et al3 and Mithoefer et al7 integrated MDMA dosing within eight-hour
psychotherapy sessions. The blind was maintained in both studies until a third, primarily
open-label session was carried out. The interpretation of the third psychotherapy session
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results is limited, as the blind was broken, and a control group for comparison no longer
existed. Oehen et al3 broke the blind in their study as soon as the second therapy session
(“stage 2”) for individuals in the active placebo group.
Mithoefer et al7 randomized a larger sample size of 103 patients. Seventy-two
patients received active doses of MDMA (75-125 mg), and 31 patients received placebo
or control doses (0-40 mg), all during eight-hour psychotherapy sessions. Consistent with
the other MDMA-assisted RCTs, CAPS scores served to diagnose and measure changes
in PTSD and depressive symptoms. This study was the longest in consideration, from
2004 to 2017, in various sites globally, from private practices to a psychiatric clinic.7
After two psychotherapy sessions, 54.2% of the experimental group participants did not
meet CAPS diagnostic criteria for PTSD compared to 22.6% in the control group.7 The
overall effect of treatment was rated according to between-group Cohen’s d effect size,
yielding a statistically significant value of 0.8.7 Following a third psychotherapy session,
symptom improvement continued to be more notable in the active dose group. PTSD
diagnoses in the Ot’alora et al15 study was significantly reduced in the group receiving
125 mg, with a mean variation from baseline CAPS scores to the one-month endpoint of
−26.3. Secondly was the 100 mg group with a mean shift of -24.4, followed by the 40 mg
active placebo group with a -11.5 change.15
Two RCTs, an SR, and a retrospective cohort study were appraised to draw a
comparison between the effects of Ketamine in the setting of treatment-resistant mood
and anxiety spectrum disorders. Feder et al17 and Murrough et al19 followed similar
procedures, organizing an experimental group of ketamine infusions and a control group
of intravenous (IV) midazolam. Murrough et al19 explicitly discussed the potential of
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Ketamine in reducing suicidal ideations (SI), measured according to the Beck Scale for
Suicidal Ideation (BSI). This RCT provides initial support regarding the safety and
tolerability of Ketamine in the setting of patients presenting with SI and risk for suicidal
behavior. Though the twenty-four-hour post-infusion BSI score alterations were not
considered statistically significant, the experimental group did experience a noteworthy
change occurring at hour 48 (p= 0.047) in comparison to the control group.19
A retrospective study of 37 patients by Hartberg et al16 conveys similar
effectiveness in Ketamine’s ability to reduce the number and duration of psychiatric
hospital admissions by comparing the total of before and after ketamine intervention. The
results portrayed a 70% reduction in hospital days and a 5% reduction in hospital
admissions.16 These cumulative findings establish a basis for future, well-powered studies
concerning the efficacy of Ketamine in patients with mood disorders such as PTSD.
Feder et al17 developed a proof-of-concept RCT establishing clinically significant
CAPS scoring measures in patients who responded more to NMDA receptor modulation
than midazolam. This trial provided the first randomized, controlled evidence that
Ketamine can lead to a rapid clinical reduction of PTSD symptoms in chronic PTSD
scenarios.17 A mean difference in Impact of Event Scale-Revised (IES-R) scores outlined
the primary outcomes of this study, with a more substantial decline in the ketamine
cohort than midazolam (mean difference, 12.7 [95% CI, 2.5-22.8]; P = .02).17
Li et al18 organized an SR analyzing six RCTs and one evidence-based guideline,
investigating the clinical effectiveness, cost-effectiveness, and procedures for IV
ketamine in treating adult patients with TRD and PTSD. In summary, three RCTs
reported IV ketamine proved more effective than placebo (Fava et al) or midazolam
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(Chen et al and Phillips et al) in remedying TRD.18 On the contrary, the evidence-based
guideline reported a strong recommendation against treating PTSD with Ketamine. This
statement was made under the declaration of ketamine use as a monotherapy, supporting
a greater efficacy in the setting of psychotherapy.18
Varker et al9 organized an SR examining the value of the psychoactive drugs
ketamine, MDMA, lysergic acid diethylamide (LSD), and psilocybin in treating PTSD.
The study grew to predominately compare Ketamine and MDMA as trials on LSD or
psilocybin failed to be identified. The findings of the SR denounced any value to
Ketamine as a standalone treatment in reducing CAPS scores, with a remission rate of
PTSD symptoms of 80%.9 In a direct comparison of ketamine-assisted psychotherapy to
MDMA-assisted psychotherapy, the evidence for MDMA was superior (defined as
“moderate”) to the evidence associated with Ketamine (defined as “low”).9
Recommendations for Future Research
Recommendations for future research include establishing an optimal dose of MDMA in
the clinical setting. However, all three RCTs on MDMA-assisted psychotherapy administered at
least 100 mg doses in their experimental groups.3,7,15 The effects of one-time dosing versus
continued supplemental dosing have also not been explored by these studies. In addition to
lacking a defined optimal dose or optimal dosing regimen, all studies indicated a need for more
well-powered studies to generate further evidence.
CONCLUSION OF LITERATURE REVIEW
Based on the literature review, there was sufficient evidence to suggest that using
MDMA during psychotherapy sessions could limit the incidence of PTSD and reduce its
associative symptoms of depression.3,7,9,15 Comparison to Ketamine served to solidify the existing
evidence supporting MDMA usage. Despite varying conclusions on Ketamine’s efficacy in
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patients with mental health disorders, it is still a more accepted treatment modality utilized in
practice.
METHODOLOGY OF QUALITY IMPROVEMENT
Setting
The setting for this project was a 672-bed hospital in Miami Beach, Florida. Mount Sinai
Medical Center (MSMC) is an independent, non-profit teaching hospital in Miami-Dade County.
There is a significant elderly population in this county, with 22% over the age of 60.20 Miami
Beach Anesthesiology Associates (MBAA) provides anesthesia services in 12 operating rooms,
an eight-bed gastrointestinal (GI) suite, a catheterization lab, in addition to multiple other areas on
campus.
Recruitment
Before the recruitment of this learning module’s participants, approval was obtained by
the investigators from Florida International University (FIU) and MBAA at MSMC. Certified
registered nurse anesthetists (CRNAs) and anesthesiologists made up the population of interest.
MBAA provided a contact list inclusive of the target group, and recruitment was carried out
virtually utilizing e-mail.
Project Participants
Eligibility was defined as full-time and part-time CRNAs employed by MBAA and
working at MSMC. A total of 20 anesthesia providers were invited to pursue this learning
module. Participation of student registered nurse anesthetists (SRNAs) was excluded from this
project.
Intervention
This evidence-based education module was executed in stages. The intervention consists
of a recruitment phase, a pre-test, an educational intervention, and finally, a post-test. Pretesting
is administered to obtain a baseline of the participant’s understanding of MDMA and the current
inefficiencies of PTSD management in the clinical setting. Following the pre-test, subjects
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listened to an evidence-based voiceover PowerPoint education module that identifies the need for
improved PTSD treatment, states the occurrence of lifetime PTSD in North American adults, and
identifies factors that have prevented MDMA as a viable clinical adjuvant. The module also
defines and contrasts MDMA from Ecstasy, describes previous clinical effects associated with
MDMA, and identifies the potential for future MDMA use in the clinical setting. The educational
content is supported by the literature review and is referenced accordingly. Participants will take
a post-test to determine learning module efficacy, knowledge growth, and overall subject matter
interest following the learning intervention.
Procedures
Participation was instigated through an e-mail list of providers supplied by MBAA.
Enclosed in the e-mail was an anonymous link to a pre-intervention questionnaire using the
Qualtrics survey platform. The educational module was provided virtually and made available to
subjects through e-mail. After completing the learning module, post-testing was carried out in the
same fashion utilizing the Qualtrics survey platform. No personal or identifiable information was
sought after or acquired throughout testing. The only item needed by the learner was either a
computer or cell phone.
Protection of Human Subjects
As this is an educational intervention, there is no to minimal risk to participants. Risks
were outlined in the consent (see Appendix B). Anonymity was ensured under the Qualtrics
survey platform, and the investigator obtained no personal factors that could identify the subjects.
Additionally, Institutional Review Board (IRB) approval was gained before any intervention was
carried out (see Appendix C). All anonymous results were maintained on a password-protected
computer.
Measurement
The data was exported from Qualtrics to the Statistical Package for the Social Sciences
(SPSS), and an analysis was conducted. Descriptive statistics were utilized on pre and post-test
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data sets to examine survey responses. A paired t-test was then performed, inspecting the
significance of changes in knowledge and attitudes of anesthesia providers secondary to the
educational intervention.
Analysis
The co-investigator DNP student will extrapolate statistically significant data from SPSS,
utilizing this to establish patterns of change from participants. Growth or decline in knowledge
from pre-test to post-test will be compared using random identification numbers (ID) allocated by
the Qualtrics platform to preserve anonymity. Each question will be assessed, and measurements
will be taken to establish personal change, change amongst the group, and the overall
effectiveness of the educational intervention. Data collected will remain on a password-protected
computer.
RESULTS OF QUALITY IMPROVEMENT
Pre-test and Post-test Sample
The pre-test demographics are identified in Table 2., shown below.
Table 2. Pre-Intervention and Post-Intervention Participation Demographic Data
Demographics

N (%)

Total Participants

8 (100%)

Gender
Male

3 (37.5%)

Female

5 (62.5%)

Age
25 -Ge
35 yr.

5 (62.5%)

36 - 45 yr.

1 (12.5%)

46 – 55 yr.

2 (25%)

55 – 66 yr.

0 (0%)

Ethnicity
Hispanic

4 (50%)

Caucasian

0 (0%)

African American

2 (25%)
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Asian

1 (12.5%)

Other

1 (12.5%)

Education
Masters

0 (0%)

Doctorate

8 (100%)

Years of Practice
0 – 2 yr.

4 (50%)

2 – 5 yr.

1 (12.5%)

5 – 10 yr.

1 (12.5%)

10 – 20 yr.

2 (25%)

Sixteen individuals initially started the pre-test survey, six of which failed to complete the
post-test survey. Two CRNAs neglected to enter their random ID number to allow the project’s
co-investigator to assign pre and post-test scores to the right surveyor. Subsequently, their data
was omitted during dissemination.
Eight anesthesia providers accurately followed the pre-test and post-test instructions, and
their demographics are presented in Table 2. Most of the participants were female (n=5, 62.5%),
instead of male (n=3, 37.5%). Most individuals were also amongst the 25 to 35 age group (n=5,
62.5%). The remaining participant’s ages were as follows: 36 to 45 years old (n=1, 12.5%), 46 to
55 years old (n=2, 25%), and no individuals from the 55 to 66-year age group. Various ethnicities
were also represented amongst the surveyor’s: Hispanic (n=4, 50%), African American (n=1,
12.5%), Asian (n=1, 12.5%), and other (n=1, 12.5%). There were no participants who identified
as Caucasian. All participants were CRNAs with Doctoral degrees (n=8, 100%). Finally,
individuals were asked about their years of CRNA practice: 0 - 2 years (n=4, 50%), 2 - 5 years
(n=1, 12.5%), 5 - 10 years (n = 1, 12.5%), 10 - 20 years (n=2, 25%).
Pre-test Identification of Knowledge of PTSD Sequelae and Efficiencies of Treatment
Modalities
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The pre-test consisted of nine questions that assessed participants’ baseline knowledge on
the topics being measured by the investigators. These topics included current first-line treatment
modalities for PTSD, the overall efficacy of the first-line modality, lifetime effects and incidences
of PTSD, MDMA’s history, mechanism of action, and side effect profile, how MDMA differs
from Ecstasy, and MDMA’s current FDA standing on approval. Pre-test scores are subsequently
organized in Table 3.
Regarding the first-line treatment for PTSD identified by the APA, only two participants
(25%) identified this correctly as psychotherapies. One participant (12.5%) rightly answered the
average response to this mode of therapy as averaging around 10 to 20 percent. Nearly all
interviewees (n=7, 87.5%) were aware of the lifetime effects and comorbid conditions associated
with PTSD. Additionally, the lifetime incidence of PTSD across North America was answered
correctly by five participants (n= 62.5%) as 6 to 9 percent.
Pre-test Identification of Current Knowledge and Perspective of MDMA-Assisted
Psychotherapies
A general knowledge deficit of MDMA’s history was recognized, with no participants
(n=0, 0%) accurately distinguishing that MDMA originated from a precursor to a hemostatic
substance. An understanding of how MDMA and Ecstasy differ was mixed amongst the group.
Three providers (37.5%) correctly identified that MDMA is an abbreviated version of a single
chemical compound in Ecstasy. Another three participants (37.5%) believed MDMA lacked the
psychedelic properties of Ecstasy, and 25% answered MDMA contains an additional amine
group. Only 2 participants (25%) confirmed MDMA’s mechanism of action as a disrupter of the
reuptake transport protein SERT, and 3 participants (37.5%) rightly identified that nystagmus was
not a commonly reported MDMA side effect. A preponderance of the group (n=5, 62.5%) was
aware at baseline that MDMA-assisted psychotherapy for PTSD management has not yet been
approved by the FDA nor been made widely available. Following item analysis in SPSS, the
average score for the pre-test knowledge assessment was 3.5 (SD=0.53).
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Post-Test Identification of Knowledge of PTSD Sequelae and Efficiencies of Current
Treatment Modalities
Following the PowerPoint educational module voluntarily viewed by participants, all
eight individuals were retested on the same questions to establish any growth in knowledge. Most
notably, a 50% (n=4) gain in knowledge was observed regarding identifying psychotherapies as
the first line for PTSD treatment. 62.5% (n=5) of the participants correctly answered the North
American lifetime PTSD incidence range, with a 12.5% increase identified from pre-test analysis.
Pre-test and post-test scores remained consistent regarding PTSD’s sequela and
associative comorbid ailments, with seven participants answering rightly under both pre and posttest conditions (87.5%). In addition, only one participant correctly identified the 10 to 20 percent
response rate in patients receiving pharmacotherapies for PTSD treatments. Resultantly, this
demonstrated an unexpected lack of knowledge growth between pre and post-testing.
Post-Test Identification of Current Knowledge and Perspective of MDMA-Assisted
Psychotherapies
A 62.5% growth in knowledge was seen between pre and post-testing regarding
MDMA’s origin as a hemostatic substance. Five participants were able to identify this correctly
following the educational intervention. Additionally, most participants (n=5) could also discern
MDMA as an abbreviated version of a single chemical compound within Ecstasy tablets,
reflecting a 25% knowledge growth from pre- to post-testing regarding the difference between
MDMA and Ecstasy.
Knowledge was also gained by participants regarding MDMA’s mechanism of action.
Out of all eight participants, seven (87.5%) understood MDMA to be a substance that renders its
effects via the disruption of the reuptake transport protein, SERT. Similarly, seven individuals
(87.5%) from only 3 (37.5%) who answered correctly during pre-testing became aware that
nystagmus was not an expected side effect of MDMA. Most of the group, plus an additional
participant who originally answered incorrectly on pre-testing (n=6, 75%), was aware that
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MDMA-assisted psychotherapy for PTSD management has not yet been approved by the FDA
nor been made widely available. Overall, the average score for the post-test knowledge following
the education module was 6.25(SD=2.43).
Table 3. Difference in Pre- and Post-Test Responses (Knowledge of PTSD Sequelae and
Efficiencies of Current Treatment Modalities)
PRE-TEST

POST-TEST

DIFFERENCE

ACCORDING TO THE AMERICAN
PSYCHOLOGICAL APPLICATION’S (APA’S)
2017 CLINICAL PRACTICE GUIDELINES, THE
FIRST-LINE TREATMENT FOR PTSD HAS
BEEN IDENTIFIED AS: PSYCHOTHERAPIES

25%

75%

50%

OF PATIENTS RECEIVING
PHARMACOTHERAPY FOR PTSD
TREATMENT, HOW MANY RESPOND TO
THERAPIES? 10 TO 20%
PTSD CONTRIBUTES TO REDUCED LIFE
QUALITY AND THE DEVELOPMENT OF
COMORBID CONDITIONS SUCH AS: ALL
THE ABOVE (EMERGENCE DELIRIUM,
DEPRESSION, HYPERTENSION, OBESITY)
THE LIFETIME INCIDENCE OF PTSD IN
ADULT AGED SAMPLES IN THE UNITED
STATES AND CANADA RANGES FROM: 6 TO
9%

12.5%

12.5%

0%

87.5%

87.5%

0%

62.5%

75%

CORRECT RESPONSES

12.5%

Table 4. Difference in Pre- and Post-Test Responses (Knowledge and Perspective of
MDMA-Assisted Psychotherapies)
CORRECT RESPONSES

PRETEST

POST-

DIFFERENCE

TEST
HOW DOES MDMA DIFFER FROM
ECSTASY? MDMA IS AN ABBREVIATED
VERSION OF A SINGLE CHEMICAL
COMPOUND THAT IS A COMPONENT OF
ECSTASY TABLETS
WHICH OF THE FOLLOWING IS CORRECT
REGARDING THE PHARMACOLOGY OF
MDMA? CAUSES DISRUPTION OF THE
REUPTAKE TRANSPORT PROTEIN SERT
MDMA-ASSISTED THERAPY FOR PTSD HAS:
NOT YET BEEN APPROVED BY THE FDA

37.5%

62.5%

25%

25%

87.5%

62.5%
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AND HAS NOT BEEN MADE WIDELY
AVAILABLE
ALL OF THE FOLLOWING ARE COMMONLY
REPORTED SIDE EFFECTS OF MDMA
PSYCHOTHERAPY EXCEPT: NYSTAGMUS
3-4
METHYLENEDIOXYMETHAMPHETAMINE
(MDMA) WAS ORIGINALLY DEVELOPED
WITH WHAT PHARMACOLOGIC
INTENTION: PRECURSOR TO A
HEMOSTATIC SUBSTANCE

62.5%

75%

12.5%

37.5%

87.5%

50%

0%

62.5%

62.5%

Table 5. Difference in Pre- and Post-Test (Interest in MDMA use in clinical setting)
HOW LIKELY ARE YOU TO
INVESTIGATE THIS NOVEL TREATMENT
MODALITY ON YOUR OWN?
MOST LIKELY

PRE-TEST

POST-TEST

DIFFERENCE

25%

25%

0%

SOMEWHAT LIKELY

25%

25%

0%

SOMEWHAT UNLIKELY

50%

50%

0%

MOST UNLIKELY

0%

0%

0%

Table 5 depicts changes in the CRNA’s perspective regarding the use of MDMA in the
clinical setting. Overall, scores did not vary. Participants maintained the same level of interest or
disinterest in the topic before and after the educational intervention.
DISCUSSION OF QUALITY IMPROVEMENT
Summary of Data
The results demonstrate an overall gain in knowledge between pre and post-testing, with
only one participant with a lower post-test from pre-test score.
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Individual Results of Participants
100%
80%
60%
40%
20%
0%
1

2

3

4

5

Pre-test

Post-test

Difference

6

7

8

-20%
-40%

The average pre-test score of all participants was a 38.9%. Compared to the average post-test
score of 69.5%, a 30.6% increase in knowledge was realized. The average improvement between
individual pre-and post-testing was 30.3%. Only one (n=1, 12.5%) out of the eight participants
showed a decline in knowledge following the education provided. The remaining seven
anesthesia providers (n=7, 87.5%) increased their understanding of PTSD and MDMA.
Table 6. Paired T-test

Following data extrapolation from SPSS and according to the paired T-test, the mean
change was 2.75, indicating that the average knowledge increase was 2.75 points higher on the
post-test when compared to the pre-test. The results show a P value of 0.014, which is well below
the statistically significant indicator of 0.05. The paired T-test demonstrates a statically
significant knowledge base increase from the pre-test to the post-test due to the education module
provided to participants.
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Limitations
Limitations of this study include a small sample size that was not gender or age balanced.
The bulk of participants were females (n=5, 62.5%) aged 25 to 35 (n=5, 62.5%). An increase in
sample size would more accurately reflect the population of interest and improve the reliability of
the study. Innate to qualitative research and secondary to the vastness of the topics of interest,
PTSD and MDMA utilization, questions of improved quality and less subjectivity may have also
altered pre-and post-testing scores.
As this project was volunteer-based, there is an inherent risk of self-selection bias.
Though the investigators strived for concise instructions on the survey link, six participants who
completed the pre-test failed to finish the post-test. Further, two individuals who finished their
pre-and post-testing neglected to enter their ID number as instructed. The delivery method of an
online study may have also limited the results.
Future Implications for Advanced Nursing Practice
The use of MDMA in a clinical setting has been proven safe and effective throughout
multiple RCTs. Still, additional evaluation is required before MDMA can be taken seriously as a
potential treatment modality. The outcomes of this study are essential in determining effective
strategies to educate CRNAs on the need for enhanced treatments for PTSD and its associative
symptoms of depression and the current data on the utilization of MDMA in practice. According
to the information collected, the educational intervention successfully improved anesthesia
provider knowledge of the sequelae of PTSD, inefficiencies of current PTSD treatment
modalities, and MDMA as a clinical adjuvant. The results of this study can be applied to a
broader population to develop a greater understanding of a clinician’s willingness to investigate
and approach MDMA administration. Coupled with evidence generated from the systematic
review, the results of this study could drive future extension of MDMA-assisted psychotherapy
into phase three trials and ultimately as a potential anesthetic option.
Conclusions
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As denoted throughout the research, individuals with PTSD and accompanying MDD
represent a subpopulation prone to a sequela of other comorbid conditions. This puts these
patients in an increased need for both medical and surgical services. There is an undeniable need
for more research to improve patient treatment options. An area of vulnerability for these patients
is the perioperative period, where a standard of care is lacking. As supported by the SR, these
individuals are more likely to experience ED, yielding unintentionally prolonged hospital stays
and increased morbidity and mortality.
MDMA’s use as an adjuvant to therapy has been and continues to be explored. MDMA’s
psychedelic and dissociative properties are somewhat comparable to Ketamine, an IV anesthetic
grossly accepted by the clinical community. The outcomes of this study assist in gauging the
CRNA’s willingness to approach novel treatment modalities in the face of specialty populations
who need it most. More specifically, patients who have PTSD have widely benefitted from
MDMA-assisted psychotherapy throughout copious RCTs and phase 2 trials.
Though providers’ attitudes regarding MDMA as a clinical adjuvant did not change
secondary to the learning module, there was some interest at baseline. A statically significant
knowledge base increase was shown following the intervention, proving the PowerPoint a
valuable tool in expanding CRNA’s learning. Though there remains a long way to go, there is a
potential future for MDMA’s use in the clinical setting.
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Thank you for inviting Mount Sinai Medical Center to participate in Doctor of Nursing Practice (DNP) project
conducted by Brittany Williams entitled “An Evidence Based Learning Module Implementation to Expand
CRNA Knowledge of Post-Traumatic Stress Disorder (PTSD) and the Use of 3,4Methylenedioxymethamphetamine (MDMA) Assisted Psychotherapies in Patients who have PTSD and
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support the participation of our Anesthesiology providers in this project and look forward to working with
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Jampierre (J.P.) Mato, DNP, CRNA, APRN
Executive CRNA Director
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ADULT ONLINE CONSENT TO PARTICIPATE IN A RESEARCH STUDY
“A Learning Module in Post-Traumatic Stress Disorder (PTSD) and the Use of 3,4Methylenedioxymethamphetamine (MDMA) Assisted Psychotherapies in Patients who have
PTSD and Other Alike Disorders
SUMMARY INFORMATION
Things you should know about this study:
•
•
•
•

•
•
•

Purpose: This project aims to increase the provider's understanding of 3,4Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in the setting of
Post-Traumatic Stress Disorder (PTSD).
Procedures: If you choose to participate, you will be asked to complete an e-mailed
pre-test/post-test and watch a virtual educational voiceover PowerPoint.
Duration: This will take about 20 minutes of your time
Risks: There will be minimal risks involved with this project, as would be expected in
any type of educational intervention, which may have included mild emotional stress
or mild physical discomfort from sitting on a chair for an extended period of time, for
instance.
Benefits: The main benefit to you from this research is: Increase the knowledge of
anesthesia providers on the use of MDMA as a source of psychotherapy and the
anesthesia considerations of caring for patients who use these drugs for therapy
Alternatives: There are no known alternatives available to you other than not taking
part in this study.
Participation: Taking part in this research project is voluntary.

Please carefully read the entire document before agreeing to participate.
PURPOSE OF THE PROJECT
You are being asked to be in a quality improvement project. The purpose of this project is to
increase the provider's understanding of 3,4-Methylenedioxymethamphetamine (MDMA)assisted psychotherapy in the setting of Post-Traumatic Stress Disorder (PTSD).
NUMBER OF STUDY PARTICIPANTS
If you decide to be in this study, you will be one of 20 people in this research study.
DURATION OF THE PROJECT
Your participation will require about 20 minutes of your time.
PROCEDURES
If you agree to be in the project, we will ask you to do the following things:
• Complete an online 10 question pre-test survey via Qualtrics, an online survey product
for which the URL link is provided
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•
•

Review the educational PowerPoint module lasting 10 minutes via Qualtrics and online
survey for which the URL link is provided
Complete the online 10 question post-test survey via Qualtrics, an online survey product
for which the URL link is provided

RISKS AND/OR DISCOMFORTS
There will be minimal risks involved with this project, as expected in any type of educational
intervention, which may have included mild emotional stress or mild physical discomfort from
sitting on a chair for an extended period of time.
BENEFITS
The following benefits may be associated with your participation in this project: Increase the
knowledge of anesthesia providers on the use of MDMA as a source of psychotherapy and the
anesthesia considerations of caring for patients who use these drugs for therapy. The overall
objective of the program is to increase the quality of healthcare delivery, improve the health of
our patients, and increase patient engagement.
ALTERNATIVES
There are no known alternatives available to you other than not taking part in this project.
However, if you would like to receive the educational material given to the participants in this
project, it will be provided to you at no cost.
CONFIDENTIALITY
The records of this project will be kept private and will be protected to the fullest extent provided
by law. If we might publish any sort of report, we will not include any information that will make
it possible to identify you as a participant. Records will be stored securely, and only the project
team will have access to the records.
COMPENSATION & COSTS
There is no cost or payment to you for receiving the health education and/or participating in this
project.
RIGHT TO DECLINE OR WITHDRAW
Your participation in this project is voluntary. You are free to participate in the project or
withdraw your consent at any time during the project. Your withdrawal or lack of participation
will not affect any benefits to which you are otherwise entitled. The investigator reserves the right
to remove you without your consent at such a time that they feel it is in the best interest.
RESEARCHER CONTACT INFORMATION
If you have any questions about the purpose, procedures, or any other issues relating to this
research project, you may contact Brittany Williams at 772-475-4254, bwill192@fiu.edu
or Dr. Yasmine Campbell, 305-348-9894, ycampbel@fiu.edu.
IRB CONTACT INFORMATION
If you would like to talk with someone about your rights of being a subject in this project or about
ethical issues with this project, you may contact the FIU Office of Research Integrity by phone at
305-348-2494 or by e-mail at ori@fiu.edu
PARTICIPANT AGREEMENT
I consent by participating in the survey. I have read the information in this consent form and
agree to participate in this project.
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Office of Research Integrity
Research Compliance, MARC 414

MEMORANDUM
To:
CC:

Dr. Yasmine Campbell
Brittany Williams

From:

Maria Melendez-Vargas, MIBA, IRB Coordinator

Date:

April 7, 2021

Protocol Title:

“An Evidence Based Educational Module On Anesthesia Considerations On
Patients With MDMA Assisted Psychotherapy In The Reduction of PostTraumatic Stress Disorder Symptoms”

The Florida International University Office of Research Integrity has reviewed your research
study for the use of human subjects and deemed it Exempt via the Exempt Review process.
IRB Protocol Exemption #:
TOPAZ Reference #:

IRB-21-0137
110225

IRB Exemption Date:

04/07/21

As a requirement of IRB Exemption you are required to:
1) Submit an IRB Exempt Amendment Form for all proposed additions or changes in the
procedures involving human subjects. All additions and changes must be reviewed and
approved prior to implementation.
2) Promptly submit an IRB Exempt Event Report Form for every serious or unusual or
unanticipated adverse event, problems with the rights or welfare of the human subjects,
and/or deviations from the approved protocol.
3) Submit an IRB Exempt Project Completion Report Form when the study is finished or
discontinued.
Special Conditions: N/A

For further information, you may visit the IRB website at http://research.fiu.edu/irb.
MMV/em
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Nicole Wertheim College of Nursing and Health Sciences
Department of Nurse Anesthetist Practice
Uses of Immersive Virtual Reality Distraction as an adjunct to anesthesia to decrease levels
of pain in patients experiencing acute procedural pain: An Evidence-Based Educational
Module
Dear Mount Sinai Medical Anesthesia Department,
My name is Brittany Williams, and I am a student from the Anesthesiology Nursing Program
Department of Nurse Anesthetist Practice at Florida International University. I am writing to
invite you to participate in my quality improvement project. This project aims to improve health
care provider knowledge regarding PTSD and the existing body of research of MDMA-assisted
psychotherapies in patients suffering from this disorder and others alike.
You are eligible to participate in this project because you are a Mount Sinai Medical Anesthesia
Department member.
If you decide to participate in this project, you will be asked to complete and sign a consent form
for participation. Next, you will complete a pre-test questionnaire, which is expected to take
approximately 5 minutes. You will then be asked to view an approximately 15-minute-long
educational presentation online. After watching the video, you will be asked to complete the posttest questionnaire, which is expected to take approximately 5 minutes. No compensation will be
provided.
Remember, this is completely voluntary. You can choose to be in the study or not. If you’d like to
participate or have any questions about the study, please e-mail or contact me at
bwill192@fiu.edu or 772-475-4254.
Thank you very much.
Sincerely,
Brittany Williams, SRNA, BSN, CCRN

Appendix E

The primary aim of this QI project is to expand the knowledge of CRNAs regarding PTSD and
the existing body of research of MDMA-assisted psychotherapies in patients suffering from this
disorder and others alike.
Please answer the question below to the best of your ability. The questions are in multiple-choice
format and are meant to measure knowledge and perceptions of MDMA in the clinical setting.
By clicking the “next” button, you acknowledge that your participation in this study is voluntary,
you are at least 18 years of age, and that you may choose to terminate your participation in the
study at any time and for any reason.
Demographic Questions
-

-

Gender:
o Male
o Female
o Other
Age:
o _______

-

Ethnicity:
o Hispanic
o Caucasian
o African American
o Asian
o Other

-

Position/title:
o _______

-

Level of Education:
o Bachelors
o Masters
o Other ______

-

How many years have you been an anesthesia provider?
o 1-2 years
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o
o
o

2-5 years
5-10 years
> 10 years

Knowledge
According to the American Psychological Association’s (APA’s) 2017 clinical
practice guidelines, the first-line treatment for PTSD has been identified as:
a. SSRI therapy
b. SNRI therapy
c. Long-term counseling
d. Psychotherapies
Of patient’s receiving pharmacotherapy for PTSD treatment, how many respond to
therapies?
a. 5 to 10%
b. 10 to 20%
c. 20 to 30%
d. 30 to 40%
3,4-Methylenedioxymethamphetamine (MDMA) was originally developed with what
pharmacologic intention:
a. Appetite suppressant
b. Originated as a psychedelic used only recreationally
c. Precursor to a hemostatic substance
d. Analgesic
PTSD contributes to reduced life quality and the development of comorbid
conditions such as:
a. Emergence delirium
b. Depression
c. Hypertension
d. Obesity
e. All the above
How does MDMA differ from Ecstasy?
a. MDMA is an abbreviated version of a single chemical compound that is a
component of Ecstasy tablets
b. It doesn’t, they are the same substance
c. MDMA contains an additional amine group
d. MDMA lacks the psychedelic properties of Ecstasy
The lifetime incidence of PTSD in adult aged samples in the United States and
Canada ranges from?
a. 1 to 5 %
b. 6 to 9 %
c. 20 to 24 %
d. 45 to 51 %
Which of the following is CORRECT regarding the pharmacology of MDMA?
a. Causes disruption of the reuptake transport protein SERT.

40
b. Enhances GABA receptor modulation
c. Its administration increases the net release of monoamine neurotransmitters from
axon terminals
d. It increases Na+ channel resting membrane potential
MDMA-assisted therapy for PTSD has:
a. Has not yet been approved by the FDA but has been made widely available
b. Has been approved by the FDA but has not been made widely available
c. Has not yet been approved by the FDA and has not been made widely available
All the following are commonly reported side effects of MDMA psychotherapy
EXCEPT:
a. Nystagmus
b. Elevated blood pressure
c. Tachycardia
d. Anxiolysis
How likely are you to investigate this novel treatment modality on your own?
a. Most likely
b. Somewhat likely
c. Somewhat unlikely
d. Most unlikely
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Evaluation Table 1

Citation and
Theme of
the article

Design/Met
hod

Sample/Settin
g

Major
Variables
Studied and
Their
Definitions

Measurement
And Data
Analysis

Findings

Results

Conclusions

Appraisal:
Worth to
Practice/Leve
l

Oehen P,
Traber R,
Widmer V,
Schnyder U.
A
randomized,
controlled
pilot study
of MDMA (±
3,4methylenedi
oxymetham
phetamine)assisted
psychothera
py for
treatment of
resistant,
chronic
posttraumatic
stress
disorder
(PTSD). J
Psychophar
macol.
2013;27(1):4
0-52. doi:
10.1177/026
9881112464
827

RCT;
Pre/post
CAPS score
comparison
of patients in
an
experimental
group
receiving 125
mg and
62.5mg, 2.5
hours later,
of
MDMA to a
control
group of
patients
receiving
active
placebo
MDMA
doses of 25
mg followed
2.5 hours
later by 12.5
mg.

12 total
participants.
(10 females, 2
males, mean
age 41.4 with
previous
inadequate
response to
PTSD
treatment
modalities).
N=8 in the
experimental
group. N=4 in
the control
group. Drop
out (n=1), who
withdrew due
to adverse
effects after
MDMA session
1. The study
was conducted
at nondisclosed
clinical sites.
The study was
conducted in
an outpatient
setting,
including one
overnight stay
after each
MDMA session
to assess
safety.

IV1 = MDMA
therapeutic
dose
administration
vs. MDMA
subtherapeutic
dose
administration.
DVI= CAPS-IV
scores at
defined
experimental
endpoints.
DV2= PTSD
symptom
severity
measured by
the
Posttraumatic
Diagnostic
Scale (PDS)

CAPS-IV
interview
administered at
baseline (T0),
three weeks
following
second MDMA
session (T1),
three weeks
after the third
MDMA session
(T2), two
months (T3), six
months (T4),
and 12 months
(T5) following
the study’s
completion. The
scale level is
ratio because it
is quantitative
in nature.
PDS scale was
also used, a
validated selfreporting means
assessing PTSD
symptom
severity. The
scale was level
represents ratio
data. Reliability
is questionable
as an
unvalidated yet
widely used
German version
of the PDS was
used in the
study.3
CAPS and PDS
scores were
analyzed by
nonparametric
analysis of
variance
(ANOVA), using
an F1-LD-F1
model.3

CAPS change
scores by
group for
T0-T2: T0T1: Active
Placebo: -3.3
(9.9); Full
dose: -3.4
(12.0). T1T2: Active
Placebo: 6.5
(10.3); Full
dose: -12.2
(8.1) T0-T2:
Active
Placebo: -3.2
(15.3); Full
dose: -15.6
(18.1).
PDS change
scores by
the group
for time T0T2:
Active
Placebo: 7.3
(6.2); Full
dose: -8.6
(13.0)

The active
placebo
group
showed an
increase in
average
CAPS scores
from T1 to
T2, with a
final
average
CAPS
change
score of -3.2
(15.3%); the
Experimenta
l group with
full dosesubjects
showed a
decrease in
CAPS scores
by 15.6
points
(23.5%);
Change
scores from
T0-T2 in PDS
averaged a
7.3 (6.2%)
increase in
placebo
groups and
a -8.6
(13.0%)
change in
the full-dose
group.

The study
ruled
MDMAassisted
psychothera
py as a safe
option when
administere
d in a
clinical
setting. No
serious,
drug-related
adverse
outcomes
were
identified.
Though
statistically
significant
CAPS score
changes
were not
realized,
PDS selfreports
rendered
values that
were both
clinically
and
statistically
significant (p
= 0.014).
Additionally,
at 12-month
follow-ups,
CAPS scores
continued
to improve.

*Strength:
RCT, level 1a
evidence;
Primary
outcomes
measured
using the
CAPS-IV
(noted
throughout
the research
to have good
reliability and
validity).
*Limitations:
Small sample
size; interrater
reliability/dia
gnostic
adherence
only assessed
after the
study.
*Risk or
harm: effects
mild, welltolerated.
The study
points out
that the
nature of this
therapy
(reexamining
prior
traumas)
increases
distress
regardless of
full dose vs.
placebo
psychotherap
y and may
warrant a
need for
intervention
(i.e.,
medications
or additional

Theme:
Decreased
CAPS-IV
scores
secondary
to MDMAassisted
therapy;
This RCT
speaks
specifically
to the safety
of MDMA in
both
therapeutic
and

Including T3T5, in the
experimenta
l group,
CAPS-IV
scores
decreased
on average
15.6 points
(23.5%), and
PDS scores
also reduced
compared to
an increase
in the active
placebo
group;
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subtherapeu
tic doses.

Both CAPS-IV
and PDS scores
were used to
answer the
research
question. Safety
was also
assessed with
vital sign
measurement
every half-hour
for 4 hours
following
session
termination.

psychotherap
y)
*Feasibility of
use in
practice:
MDMA is not
commercially
available, and
further
research is
indicated to
verify the
results.
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Mithoefer
MC,
Feduccia AA,
Jerome L, et
al. MDMAassisted
psychothera
py for
treatment of
PTSD: Study
design and
rationale for
phase 3
trials based
on pooled
analysis of
six phase 2
randomized
controlled
trials. Psych
opharmacol
ogy (Berl).
2019;236(9):
2735-2745.
doi:
10.1007/s00
213-01905249-5.
Theme:
Decreased
CAPS-IV
scores
secondary
to MDMAassisted
therapy

RCT;
Pre/post
CAPS score
comparison
of patients in
an
experimental
group
receiving
actives
MDMA
doses (75,
100, or 125
mg) versus
the control
group who
received an
inactive
placebo or
low dose
MDMA (0,
25, 30, or
40mg) both
during 8hour
psychothera
py sessions.

One hundred
three total
patients, 44
males, and 61
females.
Experimental
group n=72.
Control group
n=31.
Participants
were primarily
Caucasian aged
18 or older
with a mean
age of 40.5
with an
inadequate
response to
previous PTSD
treatments.
Treatment
occurred at six
sites, USA (MP1, MP-8,
MP-12),
Canada (MP-4),
Switzerland
(MP-2), and
Israel
(MP-9), five of
which being
private
practices and
one a
psychiatric
clinic. The
study was
structured with
an overnight
stay following
an 8-h
psychotherapy
session.

IV1= MDMA
active dose
administration
vs. MDMA
placebo/contr
ol dose
administration.
DV1= CAPS-IV
scores at
defined
experimental
endpoints; DV
2= the postpsychotherapy
measurement
of depression
via Beck
Depression
Inventory-II
(BDI-II); DV3=
Treatmentemergent
adverse events
(TEAEs)/
serious
adverse events
(SAEs)
measured via
self-reporting.

CAPS-IV
interview
administered
during follow-up
visits at 1 and 2
months
following the
second and
third
psychotherapy
session. Scale
level
measurement
was a ratio. The
primary efficacy
evaluation was
made with a
mixed-effect
repeated
measure model
(MMRM) on
change in
CAPS-IV total
score from
baseline to post
second and post
third
experimental
session
endpoints.7
BDI-II selfreporting
assessed
symptoms of
depression, and
the data level
was a ratio.
Response
reliability was
concluded using
a four-point
Likert scale and
summed to
produce an
overall score.7
TEAEs/SAEs
were measured
via selfreporting, and
the study
concluded there
was no
unexpected
MDMA-related
side effect. The
study did not
identify a
measurement
scale. This level
scale represents
nominal data,
and the
reliability of
self-reporting
was not
assessed.

Significant
reduction of
CAPS was
distinguishe
d from
baseline to
session #2
[t(95) = −
4.25, P <
0.0001]
between
both the
control and
active
groups. The
most
notable
changes,
however,
were viewed
within an
estimated
mean (SE)
drop in
scores
between
experimenta
l and control
cohorts (−
30.4 (3.20)
and − 10.5
(4.46)
respectively)
; Ultimate
findings can
be
summarized
as 54.2% of
participants
in the
experimenta
l group not
meeting
PTSD
diagnostic
criteria
compared to
22.6% of
those in the
placebo/con
trol group.

The
experiment
al group
demonstrat
ed
significantly
improved
CAPS-IV
score
reductions
from
baseline
compared
to the
control with
an MMRM
SE
difference
of − 22.0
(5.17), P <
0.001]
between
groups.7

The study of
MDMA in
the clinical
setting of
PTSD was
deemed
welltolerated
and
efficacious
in this trial’s
sample.
Support was
generated
to expand
MDMAassisted
psychothera
py into
phase 3
trials.

*Strengths:
RCT, level 1a.
Primary
outcomes
were
measured
with an
independent
rater using
the CAPS-IV.
Data were
pooled across
6 phase 2
trials.
Various
therapy
teams
attained
similar
findings. The
population
was near
genderbalanced.
*Limitations:
Interpretatio
n of the 3rd
experimental
session is
limited
because it
was an openlabel for most
participants
and lacked a
control
variable. The
sample size
was mostly
White/Caucas
ians. Slight
variations in
study design
existed across
all six trials.
BDI-II was
only carried
out in four of
the six
studies.
*Risk of harm
is minimal
provided
inclusion and
exclusion
criteria, was
followed for
patient
selection;
potential for
abuse,
defined by
the study as
“low.”
*Feasibility is
appropriate,
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Research
questions were
answered via
pooling data
from six phase 2
RCTs.

as proven by
the results.
However, the
true
measurement
of feasibility
relies upon
expansion
into phase 3
trials, which
cannot
happen
because
MDMA is not
commercially
available.

Evaluation Table 3

Citation and
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the article
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Sample/Settin
g
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Results
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Appraisal:
Worth to
Practice/Leve
l

Ot’aola GM,
Grigsby J,
Poulter B, et
al. 3,4methylenedi
oxymetham
phetamineassisted
psychothera
py for
treatment of
chronic
posttraumatic
stress
disorder: A
randomized
phase 2
controlled
trial. J
Psychophar
macol.
2018;32(12):
1295-1307.
doi:
10.1177/026
9881118806
297.
Theme:
Decreased
CAPS-IV
scores
secondary
to MDMAassisted
therapy

The RCT
assesses the
efficacy and
the specificdose
response of
MDMAassisted
psychothera
py via
comparing
pre and postCAPS-IV
scores in
experimental
groups
(receiving
active doses
of 100 and
125 mg) to a
low amount,
control
group (40
mg).
Following
the primary
endpoint (1months post
2nd blinded
session), the
blind was
broken with
an openlabel session
with all three
previously
defined
groups
receiving
100-125 mg
active doses
during
integrative
therapy
sessions.

Twenty-eight
patients (9
men, 19
women, mean
age of 42.0,
primarily
Caucasian)
failed to
respond to at
least one
alternate PTSD
treatment
modalities.
One participant
withdrew from
the 40 mg
control group,
and another
from the 125
mg
experimental
group (though
the study did
not disclose
why). MDMA
was
administered in
therapy rooms
of undisclosed
locations.

IV1= MDMA
therapeutic
dose
administration
vs. MDMA
subtherapeutic
dose. DV1=
postpsychotherapy
CAPS-IV
scores; DV2=
Beck
Depression
Inventory-II
(BDI-II); DV3=
Pittsburgh
Sleep Quality
Index (PSQI)
scores; DV4=
Dissociative
Experience
Scale-II (DES-II)
scores.

CAPS-IV, a ratio
scale, with
reliability in
test-re-test
method
assessed using
an analysis of
variance
(ANOVA) with
α=0.05.15
Secondary
measure’s
reliability (BDIII,
PSQI, DES-II), all
of which also
being ratio
scales, was
assessed in the
same way.

Statistically
significant
reduction in
CAPS-IV
scoring from
baseline to
one-month
s/p session 2
(defined as
stage 1 of
study).
Active dose
groups had
the most
significant
declines
(with mean
changes of
−26.3 (29.5)
for 125 mg, 24.4 (24.2)
for 100 mg,
and −11.5
(21.2) for 40
mg.) Stage 2
of study
(blind
broken)
though
supportive
of this SR’s
goal of
rationalizing
MDMA
therapy in
the setting
of
treatmentresistant
PTSD) were
then not
considered
by the
author as
breaking the
blind
reduced
internal
reliability.
At 12-month
follow-ups,
CAPS-IV
scores
dropped

The active
groups
(MDMA
doses 100
mg and 125
mg) had the
largest
reduction in
total CAPSIV scores at
the primary
endpoint
(one-month
post-study)
with SD
changes of
−26.3 (29.5)
for 125 mg,
−24.4 (24.2)
for 100 mg,
and −11.5
(21.2) for 40
mg. PTSD
symptoms
persisted in
being lower
than
baseline at
12-month
follow-up
(p<0.001),
with 76%
(n=25) not
meeting
PTSD
diagnostic
criteria.
There were
no TEAEs or
SAEs.15

MDMA in
the clinical
setting of
PTSD was
deemed
welltolerated
and
efficacious
in this trial’s
sample.
Support was
generated
to expand
MDMAassisted
psychothera
py into
phase 3
trials.

*Strength:
RCT, level 1a;
Primary
outcomes
were
measured
with an
independent
rater using
CAPS-IV.
Pooled data
across six
phase 2 trials
established
reproducible
findings. The
sample size
was near
genderbalanced.
*Limitations:
Interpretatio
n of the third
experimental
session is
limited
because it
was an openlabel for most
participants
and lacked a
control
group. The
sample size
consisted
primarily of
White/Caucas
ian. Slight
variations in
study design
existed across
all six trials
(differences
in timing of
outcome
measures,
doses tested,
number of
blinded
experimental
sessions, &
participant
number in
each dose

Cohen’s d
independentgroups pretestposttest design
was used for
comparatorsubtracted
effect size
estimates.15
Descriptive
statistics were
used to answer
the research
question by
displaying the
percentage of
participants not
meeting PTSD
criteria on
CAPS-IV
compared to
those
attaining a
>30% decrease
in scores posttreatment.
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approximate
ly -9.6, with
76% of
patients
failing to
meet PTSD
diagnostic
criteria.

Evaluation Table 4

group). BDI-II
was only
carried out in
four of the six
studies.
*Risk of harm
is minimal
provided
inclusion and
exclusion, as
defined by
the study,
were
followed for
patient
selection;
potential for
abuse,
though
defined by
the study as
“low.”
*Feasibility of
use is
appropriate
as proven by
results;
however, the
true
measurement
of feasibility
relies upon
expansion
into phase 3
trials; MDMA
is not
commercially
available.
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Appraisal:
Worth to
Practice/Leve
l

Hartberg J,
GarrettWalcott S,
De Gioannis
A. Impact of
oral
ketamine
augmentatio
n on
hospital
admissions
in
treatmentresistant
depression
and PTSD: A
retrospectiv
e
study. Psych
opharmacol
ogy (Berl).
2018;235(2):
393-398.
doi:
10.1007/s00
213-0174786-3.
Theme:
Establishes
ketamine’s
role in
MDD/PTSD
managemen
t,
legitimizing
its use as a
comparison
for this
study.

A
retrospective
cohort study
examined
ketamine
therapy on
augmentatio
n of hospital
admission in
patients
suffering
from
TRD/PTSD.

The sample
consisted of
thirty-seven
participants (28
females, nine
males, > 18
years, no
defined mean
age).
Participants
were
diagnosed with
treatmentresistant MDD,
15 with a
primary
diagnosis of
treatmentresistant PTSD.
Treatment
resistance was
explicitly
defined in the
study, and
patients were
screened using
the Kessler10.16
Retrospective
analysis design
accounts for a
0% attrition
rate. The study
reviewed the
number and
duration of
admissions to a
psychiatric
hospital before
and after
ketamine
therapy.

IV1= oral
ketamine
administration
in the setting
of treatmentresistant MDD
and PTSD.
DV1= inpatient
hospital days
in total.
DV2= hospital
admissions for
each patient
before vs.
after ketamine
therapy. DV3=
BP readings
recorded
before and 30
min after
ketamine
administration.

Outcomes were
measured using
pairwise t-tests,
which
compared total
inpatient
hospital days
and hospital
admissions pre
and post
ketamine
therapy. This
data scale is an
interval.
The reliability of
the study’s
retrospective,
match pair
analysis was not
measured.
Primary
outcomes used
to answer the
research
question
included the
number of days
spent as an
inpatient and
the number of
hospital
admissions
before and after
treatment with
Ketamine.

Of 37
patients
identified,
171 total
admissions
to
psychiatric
facilities
were
recorded
before oral
ketamine
treatment,
67
admissions
of which
credited to
symptoms of
PTSD.
Amidst the
study, 65
admissions
were
recorded (p
< 0.001).
After the
study’s
completion,
patients
were only
admitted to
the hospital
23 times.

Inpatient
hospitalizati
on days
were
reduced by
70% in the
ketamine
group, and
hospital
admissions
decreased
by 65%.

Based on
the results,
the future of
oral
Ketamine in
the clinical
setting was
identified as
a promising
pharmacolo
gic adjunct;
a stark
comparison
was made
to IM/IV
ketamine,
declaring
oral
Ketamine as
more
approachabl
e. Further
investigatio
n is both
warranted
and
supported
by this
study.

*Strengths
include level
2a evidence
with an
extensive
follow-up
period (up to
3 years).
There was
also a clear
comparison
of outcomes
between pre
and post
Ketamine
treatment
with
matched-pair
analysis.
*Limitations
included a
matching
period within
the study
that may
introduce
bias. No
controls were
named.
*Risk of harm
is limited
with this
method as it
is a
retrospective
study.
However, this
design type
may also fail
to
substantiate
the findings.
*Feasibility of
use is
moderate
since
Ketamine is
commercially
available.
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Worth to
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Feder A,
Parides MK,
Murrough
JW, et al.
Efficacy of
intravenous
ketamine
for
treatment of
chronic
posttraumatic
stress
disorder: A
randomized
clinical
trial. JAMA
Psychiatry.
2014;71(6):6
81-688. doi:
10.1001/jam
apsychiatry.
2014.62.

RCT,
comparing
an
experimental
group
receiving
Ketamine to
a control
group
receiving
midazolam
as an active
placebo.

41 Total
patients (aged
18-55.) N=22 in
the
experimental
group with a
mean age of
36.4. N=19 in
the control
group with a
mean age of
35.7. A total of
4 participants
withdrew after
the 1st therapy
session (one
found a job,
one failed to
follow up, one
was removed
due to
delayed-onset
sedation, and
one was
removed due
to low baseline
PTSD
symptoms).
Thirty-one
patients
received 2nd
infusion, with
an additional 2
participants
then
withdrawing
(one received
higher than
expected
ketamine
doses, and one
felt
uncomfortable
during infusion
therapy). Icahn
School of
Medicine
conducted the
study at Mount
Sinai’s Clinical
Research
Unit following
an overnight
fast.

IV1=IV
ketamine (0.5
mg/kg) vs
midazolam
(0.045 mg/kg).
DV1= PTSD
symptom
severity
determined by
Impact of
Event ScaleRevised (IESR); DV2= CAPS
scores; DV3=
MontgomeryAsberg
Depression
Rating Scale
(MADRS);
DV4= Quick
Inventory of
Depressive
Symptomatolo
gy, Self-Report
(QIDS-SR);
DV5= Clinical
Global
Impression–
Severity (CGIS) and–
Improvement
(GCI-I) scales.

IES-R, a ratio
scale, was used
to measure
primary
outcomes.
Secondary
outcomes were
measured using
the ratio scales
of
CAPS-IV.
MADRS,
QIDS-SR, CGI-S,
and CGI-I.

ES-R scores
24-h post
first
infusions
were
meaningfully
reduced in
experimenta
l compared
to
midazolam
(mean
difference of
12.7)

Rapid
reduction in
PTSD
symptom
severity was
established
for the first
time after
ketamine
infusions in
chronic
PTSD
patients.

A modified
intent-to-treat
analysis was
used to answer
the research
question.
An additional
intention-totreat
analysis of
covariance,
adjusting for
baseline IES-R
score,
was also
conducted with
all 41 patients
using only firstperiod data to
avoid bias and
establish
reliability.

PTSD
symptoms of
seven
patients in
the
ketamine
experimenta
l group
remained
appreciably
reduced at
two weeks
postinfusion
therapy than
in the
control
group.

More
significant
and rapid
reductions
in PTSD
symptom
severity
were seen
in the
experiment
al group
over the
control at
the 24-hour
mark.

*Strengths
include level
1a evidence.
The control
group uses an
active
placebo to
strengthen
the blind
study
(compared to
a non-active
placebo such
as saline),
shielding the
primary
outcome
analyst from
adverse
effects
occurring
during the
infusion day.
*Limitations
include that
of 41
patients, only
35 completed
the study.
Many
patients in
the
experimental
group could
correctly
guess if they
received
Ketamine due
to the higher
rates of
dissociative
symptoms.
This likely
affected the
integrity of
the blind.
*Risk of harm
is moderate.
Acute
psychological
adverse
effects
include
perceptual
disturbance,
dissociative
symptoms,
and shortterm
cognitive
impairment.
Three
patients

Theme:
Assists
establishing
ketamine’s
role in
MDD/PTSD
managemen
t,
legitimizing
its use as a
comparison
for our
study;
Supports a
basis for
further
primary
clinical
studies on
Ketamine.

MADRS and
QIDS-SR
scores at 24
hours did
not yield
significant
results
of
experiment
al vs.
control
conditions.
Analysis of
CGI-S and
CGI-I scores
at 24 hours
did yield
data
supporting
experiment
al
conditions
over
control.
Mean CAPS
score seven
days after
infusion did
not differ
significantly
by
treatment
(the mean
difference
between
groups
being
8.7 [95% CI,
−4.8 to
22.2]; P =
.20)

49
required
medical
intervention
due to
elevated BP.
*Feasibility of
use is
moderate.
Access to
Ketamine is
reliant on the
care center or
hospital; If
infusion
doses are
replicated,
these findings
are likely to
be
reproducible.
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Li KX, Loshak
H. Intraveno
us ketamine
for adults
with
treatmentresistant
depression
or posttraumatic
stress
disorder: A
review of
clinical
effectivenes
s, costeffectivenes
s and
guidelines.
Ottawa
(ON):
Canadian
Agency for
Drugs and
Technologie
s in Health;
2019. http:/
/www.ncbi.
nlm.nih.gov/
books/NBK5
51873/.

A systematic
review of the
evidence
analyzing a
total of six
RCTs and
one
evidencebased
guideline,
examining
the clinical
effectiveness
, costeffectiveness
, and
procedures
for IV
ketamine in
treating
adult
patients with
TRD/ PTSD

Four primary
studies were
identified
specific to the
clinical efficacy
of IV ketamine
in patients with
TRD in hospital
settings.
Sample sizes of
RCTs ranged
from 26 to 99
patients. The
years of study
varied, with
publications
occurring in
2017, 2018,
and 2019.

IV1= Ketamine
infusion. IV2=
Midazolam;
IV3= placebo.
DV1= antisuicidal effect
measured by
Hamilton
Depression
Rating Scale
(HAMD),
MADRS, or
Columbia
Suicide
Severity Rating
Scale (C-SSRS
SI) scores.
DV2=
depression
severity
(measured
with HAMD).

The quantitative
ratio scales of
HAMD, MADRS,
and C-SSRS SI
measured
depression/SI
reduction.
The RCTs were
assessed using
the Downs and
Black checklist.

Chen: An
RCT
concluding
decreased
suicidal
effects
measured by
HAMD and
MADRS in
both the 0.5
mg/kg and
0.2 mg/kg IV
single dose
ketamine
group
compared
with
placebo.
Ionescu: An
RCT
reporting six
repeated,
nonescalating IV
doses of 0.5
mg/kg
ketamine
was not
significantly
different
than placebo
in patients
for
antidepressa
nt or antisuicidal
efficacy.
Phillips: A
Crossover
RCT showing
decreases in
depression
severity
(measured
by MADRS
total score)
was
statistically
greater in
the
ketamine
group than
the
midazolam
group. 4-hrs
postinfusion, the
antidepressa
nt response

Ketamine
demonstrat
ed more
efficacy in
reducing the
severity of
depression
in patients
with TRD
and the
severity of
PTSD
symptoms
of patients
with PTSD.18

“Three RCTs
reported
that IV
Ketamine
was
significantly
more
effective
than
placebo and
midazolam
for the
treatment
of adults
with TRD.
One
randomized
controlled
trial
reported no
significant
difference
between IV
Ketamine
(six
repeated
doses of 0.5
mg/kg) and
placebo.
One
evidencebased
guideline
reported a
strong
recommend
ation based
on lowquality
evidence
against
treating
PTSD with
ketamine
monotherap
y. No
relevant
evidence
regarding
the clinical
effectivenes
s of IV
Ketamine
for PTSD or
the costeffectivenes
s of IV
Ketamine
for TRD or

*Strength
includes an
RCT with
level 1a
evidence.
*Limitations
include a
limited
sample size.
Studies also
took place in
varying
countries
with
inconsistent
populations.
RCT’s had
varying
follow-up
periods that
may have
influenced
results
(ranging from
14 days to
three
months). Two
studies used
single-dose
infusions of
Ketamine
instead of
repeated IV
dosing. CAPS
scoring, the
DSM-IV gold
standard for
PTSD
diagnosing,
was not used
in this study.
*Risk of harm
was reported
in 8.5% of
patients,
including
headaches,
vomiting,
worsened
depression,
and SI.
*Feasibility of
use is
moderate.
The study did
not outline
specific
guidelines
regarding the
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rate was
27% in the
ketamine
group vs. 0%
in the
midazolam
group. The
remission
rate was 5%
in the
Ketamine
group vs. 0%
in the
midazolam
group (not
compared
statically)
Fava: An RCT
showing
depression
severity (via
HAM-D-6)
was
significantly
lower in the
0.5 mg/kg
and 1.0
mg/kg IV
ketamine
groups than
placebo on
days one
and three
postinfusion. For
ketamine
doses (0.1
mg/kg and
0.2 mg/kg),
there was no
significant
difference
between
Ketamine
and placebo
in
depression
severity
changes (via
HAM-D-6).

Evaluation Table 7

PTSD was
identified.”
18

use of
Ketamine in
TRD or PTSD
patients.
However, it
did mention
an indication
for further
primary
clinical
studies,
which is the
theme of this
SR.
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Varker T,
Watson L,
Gibson K,
Forbes D,
O’Donnell
ML. Efficacy
of
psychoactiv
e drugs for
the
treatment of
posttraumatic
stress
disorder: A
systematic
review of
MDMA,
Ketamine,
LSD and
psilocybin. J
Psychoactive
Drugs.
2020:1-11.
doi:
10.1080/027
91072.2020.
1817639.
Theme:
Establishes
superiority
of MDMAassisted
psychothera
py over
ketamine
monotherap
y & assisted
therapy.

An SR that
examines the
efficacy of
MDMA,
Ketamine,
LSD, and
psilocybin
for the
treatment of
PTSD. RCTs
and
observationa
l studies
were eligible
for inclusion.
Ketamine
monotherap
y: Three
RCTs were
reviewed.
Ketamineassisted
psychothera
py: Two RCTs
examined
Ketamine in
combination
with
psychothera
py for PTSD.
MDMAassisted
psychothera
py: Four
RCTs were
examining
MDMA-AP
for chronic
PTSD.

The sample
consisted of
adult patients
(> 18 years or
older, mean
age 52.1)
diagnosed with
PTSD or
possessed a
score from a
validated
measure
indicating they
had PTSD.
Psychedelic
therapy was
administered in
various
outpatient
settings, some
trials requiring
overnight stays
after.
Participant
number varied
by study.

IV1=Ketamine
versus MDMA
(as the SR
failed to
identify trials
on LSD or
psilocybin).
DV1= CAPS
scores
determined at
varying
endpoints
depending on
the study
under review;
DV2= selfreported PTSD
symptom
improvement.

The persistence
of PTSD or
relapse was
indicated by
CAPS scores >
50. Studies were
grouped and
ranked using
GRADE
according to the
type of drug
used,
\monotherapy
or
psychotherapy,
and the posttreatment PTSD
outcomes. The
NHMRC
checklist was
used to assess
bias and thus
reliability.

Ketamine
standalone
showed
initial
improvemen
ts followed
by high
remission
rates of 80%.
Ketamine in
assisted
psychothera
py (TIMBERK) vs. control
of saline
infusions
(TIMBER-P)
showed
statistically
similar CAPS
reduction at
24-h postinfusion.
Once
TIMBER-P
participants
had relapsed
PTSD
symptoms, a
cross-over
design took
place. The
findings
determined
TIMBER-K
experiences
an increased
duration of
CAPS
reductions
(mean 24
days).
MDMA in
assisted
psychothera
py had
varied
results. In

Ketamine as
a
standalone
treatment
modality
proved low
efficacy.
Ketamineassisted
psychothera
py proved
more
effective
than
monotherap
y, though
less
effective
than
MDMAassisted
psychothera
py. MDMA
was not
measured as
a
standalone
treatment;
MDMAassisted
psychothera
py proved
the most
effective in
this SR.

The ranking
of evidence
of Ketamine
as a
standalone
treatment
was “very
low” .9
The ranking
of evidence
for
Ketamine in
combination
psychothera
py was
“low” .9 The
ranking of
evidence for
MDMA in
combination
psychothera
py was
“moderate”
.9

*Strengths
included level
1a evidence.
*Limitations
included a
small trial
number with
methodologic
al issues such
as cross-over
designs
between
experimental
and control
groups.
*Risk of harm
was
organized
according to
outcomes
realized
during each
study. One
acute
increase in
ventricular
contractions
occurred
during an
open-label
session.
*Feasibility of
use was
moderate
since
Ketamine is
commercially
available,
whereas
MDMA is not.
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the first RCT,
10 out of 12
patients in
the
experimenta
l group did
not meet
PTSD
diagnostic
criteria after
MDMA
infusion. In a
smaller RCT,
CAPS scoring
was initially
reduced in
the
experimenta
l group, but
scores did
not differ
drastically at
the 3-week
posttreatment.
At 12
months, five
participants
were free of
a PTSD
diagnosis. In
another RCT
comparing
MDMA
active doses
vs. low
doses, the
experimenta
l group
(active dose)
had the
greatest
drop in CAPS
scores.
(Mean
changes of
−26.3 for
125 mg,
−24.4 for
100 mg, and
−11.5 for 40
mg.) 9
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Murrough
JW,
Soleimani L,
DeWilde KE,
et al.
Ketamine
for rapid
reduction of
suicidal
ideation: A
randomized
controlled
trial. Psychol
Med.
2015;45(16):
3571-3580.
doi:
10.1017/S00
3329171500
1506.

RCT;
Participants
with mood
and anxiety
spectrum
disorders
(such as
MDD or
PTSD) with
clinically
significant
suicidal
ideations (SI)
were
assigned to
either an
experimental
group
receiving
(0.5mg/kg of
IV ketamine)
or an active
placebo
group
(0.045mg/kg
of IV
midazolam).

Twenty-four
total
participants (16
female, eight
males, mean
age 42.4)
Experimental
group n=12.
Control group
n= 12. The
setting was a
single-site
outpatient
psychiatric
clinic at the
Icahn School of
Medicine at
Mount Sinai
Institutional in
NY between
April 2012 and
June 2014.
No dropouts
occurred
during the
study.

IV1= Ketamine
versus
Midazolam
DV1= the Beck
Scale for
Suicidal
Ideation (BSI)
score; DV2=
MADRS-SI
score.

BSI, a ratio
scale, measured
SI at 24-h posttreatment.
MADRS-SI, also
a ratio scale,
measured
secondary
outcomes at a
24-h post and
beyond. Clinical
significance was
ascertained as a
score of >4 on
the MADRS-SI
scale. Baseline
participant
characteristics,
safety, and
tolerability
data were
analyzed using
descriptive
statistics
and t-tests or χ2
as
appropriate.19
These values
were used to
answer the
research
question

Intervention
s were well
tolerated.
24-hr posttreatment,
MADRS-SI
score was
significantly
lower in
ketamine
group
compared to
midazolam
group (1.8 ±
1.9 and 3.3 ±
1.6,
respectively,
F1,21 = 4.3,
p = 0.05,
Cohen’s d =
0.86). The
effect was
not
significant at
48 h (1.8 ±
1.9 and 3.2 ±
1.8,
respectively,
F1,21 = 3.56,
p = 0.077,
Cohen’s d =
0.77), 72 h
or seven
days.

Twentyfour-hour
postinfusion BSI
scores
changes
were not
statistically
significant;
The
experiment
al group did
experience.
However, a
noteworthy
change
occurred at
hour 48 (p=
0.047) in
comparison
to the
control
group. This
difference
lost its
significance
at either the
72 hours or
seven-day
endpoint.19

The
conclusions
of this study
provide
initial
support
regarding
the safety
and
tolerability
of Ketamine
in the
setting of
patients
presenting
with SI with
clinically
significant
risk for
suicidal
behavior.

*Strengths
include an
RCT with
level 1a
evidence.
*Limitations
include a
single-site
design. The
study could
not
demonstrate
the effects of
ketamine and
midazolam
after seven
days. BSI
baselines
were
obtained the
same day as
the study’s
initiation.
*Risk of harm
was limited
as adverse
effects that
occurred
were not
considered to
be related to
study
participation
(i.e.,
hospitalizatio
n from
worsening SI
or
depression).
*Feasibility of
use is
moderate
since
Ketamine is
commercially
available.

Theme:
Establishes a
basis for
future, wellpowered
studies
concerning
the efficacy
of Ketamine
in patients
with mood
disorders
such as
PTSD.
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